Wikidata

(Q114969615)

English

A phase II, single-arm, open label, Simon two-stage study of pembrolizumab in patients with metastatic HER2-negative breast cancer: Evaluation of impact of germline variants in APOBEC3B (AUROR).

scientific article published in 2022

In more languages

Statements

title
A phase II, single-arm, open label, Simon two-stage study of pembrolizumab in patients with metastatic HER2-negative breast cancer: Evaluation of impact of germline variants in APOBEC3B (AUROR). (English)
1 reference
stated in
Crossref
DOI
10.1200/jco.2022.40.16_suppl.1026
reference URL
https://api.crossref.org/v1/works/https://doi.org/10.1200/jco.2022.40.16_suppl.1026
retrieved
1 November 2022
author name string

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q114969615&oldid=2108829752"